DAXOR CORP 10-Q Summary: Quarter Ended September 30, 2004
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2004, for DAXOR Corporation, a New York-based company. The registrant reports on its operations, which include the marketing of the BVA-100 Blood Volume Analyzer and associated kits, alongside localized semen and blood banking services. The company maintains a significant portfolio of marketable securities, primarily utility stocks, classified as "Available-For-Sale."
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2004 | Nine Months Ended Sep 30, 2004 |
|---|---|---|
| Total Revenues | $1,119,549 | $3,183,314 |
| Operating Revenues | $277,975 | $940,958 |
| Net Income (Loss) | $(58,968) | $(300,665) |
| Net Loss Per Share | $(0.01) | $(0.06) |
| Cash and Equivalents | $64,107 (Balance Sheet) | $64,107 (Balance Sheet) |
| Marketable Securities (Fair Value) | $51,134,384 | $51,134,384 |
| Total Assets | $52,161,441 | $52,161,441 |
| Total Liabilities | $14,583,775 | $14,583,775 |
| Shareholders' Equity | $37,577,666 | $37,577,666 |
| Loans Payable | $4,394,365 | $4,394,365 |
Material Changes vs. Prior Period
- Revenue Composition: Total revenues increased 24% for the three months and 32% for the nine months compared to 2003. However, operating revenues (product sales) decreased 9% in the quarter but increased 16% for the nine months. The bulk of revenue growth is driven by investment income (dividends and capital gains).
- Profitability: The company reported a net loss for both periods, though the loss narrowed significantly compared to 2003. The nine-month net loss improved from $(702,280) in 2003 to $(300,665) in 2004, largely due to a $747,928 gain on the sale of securities.
- Expenses: Selling, General, and Administrative (SG&A) expenses rose to $2,379,960 for the nine months (up from $1,891,992 in 2003) due to expanded sales teams and R&D for the BVA-100.
- Liquidity: Cash on hand increased from $3,324 at year-end 2003 to $64,107. Loans payable increased from $2,502,106 to $4,394,365, reflecting increased margin debt and bank loans secured by the securities portfolio.
Outlook, Risks, and Management Commentary
- Strategy: Management is aggressively expanding the sales force and utilizing a "loaner" program where instruments are lent or rented to hospitals to accelerate adoption of the BVA-100. This strategy delays immediate revenue recognition from equipment sales but aims to secure long-term kit sales.
- Capital Resources: The company relies heavily on its investment portfolio (market value ~$51.1M) for liquidity. It holds significant unrealized gains ($28M pre-tax). Current liabilities include $9.5M in deferred taxes, which would only be realized if the portfolio were sold.
- Risks: The filing notes that sales cycles are long (6-12 months). The company has no long-term debt but carries short-term margin debt secured by its stock portfolio. Operating cash flows were negative ($1.17M used in nine months), offset by investing activities related to securities trading.
- Legal: No legal proceedings are reported.
Investor Verification Checklist
- Revenue Sustainability: Verify the trajectory of operating revenues versus investment income to assess the viability of the core medical device business.
- Debt Covenants: Review the terms of the $4.4M in loans payable, which are secured by the marketable securities portfolio, to understand margin call risks.
- Deferred Tax Liability: Confirm the $9.5M deferred tax liability is non-current and contingent upon the sale of the securities portfolio.
- Cash Burn: Monitor the negative operating cash flow against the company's cash reserves and ability to fund the expanded sales team.
- Unrealized Gains: Distinguish between realized cash gains and the significant unrealized holding gains included in shareholders' equity.